Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome

Giulio Disanto; Rocco Adiutori; Ruth Dobson; Vittorio Martinelli; Gloria Dalla Costa; Tessel Runia; Evgeniy Evdoshenko; Eric Thouvenot; Maria Trojano; Niklas Norgren; Charlotte Teunissen; Ludwig Kappos; Gavin Giovannoni; Jens Kuhle

doi:10.1136/jnnp-2014-309690

Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome

Giulio Disanto, Rocco Adiutori, Ruth Dobson, Vittorio Martinelli, Gloria Dalla Costa, Tessel Runia, Evgeniy Evdoshenko, Eric Thouvenot, Maria Trojano, Niklas Norgren, Charlotte Teunissen, Ludwig Kappos, Gavin Giovannoni, Jens Kuhle

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background Neurofilament light chain (NfL) represents a promising biomarker for axonal injury. We present the first exploratory study on serum NfL in patients with a clinically isolated syndrome (CIS) and healthy controls.

Methods We investigated serum NfL levels in 100 patients with CIS with a short conversion interval to clinically definite multiple sclerosis (MS) (fast converters (FC), median (IQR) conversion time: 110 days (79–139)); 98 patients with non-converting CIS (non-converters (NC), follow-up: 6.5 years (5.3–7.9)); and 92 healthy controls.

Results NfL levels were higher in FC (24.1 pg/mL (13.5–51.8)) and NC (19.3 pg/mL (13.6–35.2)) than in healthy controls (7.9 pg/mL (5.6–17.2)) (OR=5.85; 95% CI 2.63 to 13.02; p=1.5×10−5 and OR=7.03; 95% CI 2.85 to 17.34; p=2.3×10−5, respectively). When grouping FC and NC, increased serum NfL concentration was also associated with increasing numbers of T2 hyperintense MRI lesions (OR=2.36; 95% CI 1.21 to 4.59; p=0.011), gadolinium-enhancing lesions (OR=2.69; 95% CI 1.13 to 6.41; p=0.026) and higher disability scores (OR=2.54; 95% CI 1.21 to 5.31; p=0.013) at CIS diagnosis.

Conclusions If replicated in future studies, serum NfL may represent a reliable and easily accessible biomarker of early axonal damage in CIS and MS.

Original language	English
Pages (from-to)	126-129
Journal	Journal of Neurology, Neurosurgery and Psychiatry
Volume	87
Issue number	2
DOIs	https://doi.org/10.1136/jnnp-2014-309690
Publication status	Published - Feb 2016

Access to Document

10.1136/jnnp-2014-309690

Cite this

Disanto, G., Adiutori, R., Dobson, R., Martinelli, V., Costa, G. D., Runia, T., Evdoshenko, E., Thouvenot, E., Trojano, M., Norgren, N., Teunissen, C., Kappos, L., Giovannoni, G., & Kuhle, J. (2016). Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 87(2), 126-129. https://doi.org/10.1136/jnnp-2014-309690

@article{0035b12e557e4c6b8987fa8c26d859b6,

title = "Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome",

abstract = "Background Neurofilament light chain (NfL) represents a promising biomarker for axonal injury. We present the first exploratory study on serum NfL in patients with a clinically isolated syndrome (CIS) and healthy controls.Methods We investigated serum NfL levels in 100 patients with CIS with a short conversion interval to clinically definite multiple sclerosis (MS) (fast converters (FC), median (IQR) conversion time: 110 days (79–139)); 98 patients with non-converting CIS (non-converters (NC), follow-up: 6.5 years (5.3–7.9)); and 92 healthy controls.Results NfL levels were higher in FC (24.1 pg/mL (13.5–51.8)) and NC (19.3 pg/mL (13.6–35.2)) than in healthy controls (7.9 pg/mL (5.6–17.2)) (OR=5.85; 95% CI 2.63 to 13.02; p=1.5×10−5 and OR=7.03; 95% CI 2.85 to 17.34; p=2.3×10−5, respectively). When grouping FC and NC, increased serum NfL concentration was also associated with increasing numbers of T2 hyperintense MRI lesions (OR=2.36; 95% CI 1.21 to 4.59; p=0.011), gadolinium-enhancing lesions (OR=2.69; 95% CI 1.13 to 6.41; p=0.026) and higher disability scores (OR=2.54; 95% CI 1.21 to 5.31; p=0.013) at CIS diagnosis.Conclusions If replicated in future studies, serum NfL may represent a reliable and easily accessible biomarker of early axonal damage in CIS and MS.",

author = "Giulio Disanto and Rocco Adiutori and Ruth Dobson and Vittorio Martinelli and Costa, {Gloria Dalla} and Tessel Runia and Evgeniy Evdoshenko and Eric Thouvenot and Maria Trojano and Niklas Norgren and Charlotte Teunissen and Ludwig Kappos and Gavin Giovannoni and Jens Kuhle",

year = "2016",

month = feb,

doi = "10.1136/jnnp-2014-309690",

language = "English",

volume = "87",

pages = "126--129",

journal = "Journal of Neurology, Neurosurgery and Psychiatry",

issn = "0022-3050",

publisher = "BMJ Publishing Group",

number = "2",

}

Disanto, G, Adiutori, R, Dobson, R, Martinelli, V, Costa, GD, Runia, T, Evdoshenko, E, Thouvenot, E, Trojano, M, Norgren, N, Teunissen, C, Kappos, L, Giovannoni, G & Kuhle, J 2016, 'Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome', Journal of Neurology, Neurosurgery and Psychiatry, vol. 87, no. 2, pp. 126-129. https://doi.org/10.1136/jnnp-2014-309690

TY - JOUR

T1 - Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome

AU - Disanto, Giulio

AU - Adiutori, Rocco

AU - Dobson, Ruth

AU - Martinelli, Vittorio

AU - Costa, Gloria Dalla

AU - Runia, Tessel

AU - Evdoshenko, Evgeniy

AU - Thouvenot, Eric

AU - Trojano, Maria

AU - Norgren, Niklas

AU - Teunissen, Charlotte

AU - Kappos, Ludwig

AU - Giovannoni, Gavin

AU - Kuhle, Jens

PY - 2016/2

Y1 - 2016/2

N2 - Background Neurofilament light chain (NfL) represents a promising biomarker for axonal injury. We present the first exploratory study on serum NfL in patients with a clinically isolated syndrome (CIS) and healthy controls.Methods We investigated serum NfL levels in 100 patients with CIS with a short conversion interval to clinically definite multiple sclerosis (MS) (fast converters (FC), median (IQR) conversion time: 110 days (79–139)); 98 patients with non-converting CIS (non-converters (NC), follow-up: 6.5 years (5.3–7.9)); and 92 healthy controls.Results NfL levels were higher in FC (24.1 pg/mL (13.5–51.8)) and NC (19.3 pg/mL (13.6–35.2)) than in healthy controls (7.9 pg/mL (5.6–17.2)) (OR=5.85; 95% CI 2.63 to 13.02; p=1.5×10−5 and OR=7.03; 95% CI 2.85 to 17.34; p=2.3×10−5, respectively). When grouping FC and NC, increased serum NfL concentration was also associated with increasing numbers of T2 hyperintense MRI lesions (OR=2.36; 95% CI 1.21 to 4.59; p=0.011), gadolinium-enhancing lesions (OR=2.69; 95% CI 1.13 to 6.41; p=0.026) and higher disability scores (OR=2.54; 95% CI 1.21 to 5.31; p=0.013) at CIS diagnosis.Conclusions If replicated in future studies, serum NfL may represent a reliable and easily accessible biomarker of early axonal damage in CIS and MS.

AB - Background Neurofilament light chain (NfL) represents a promising biomarker for axonal injury. We present the first exploratory study on serum NfL in patients with a clinically isolated syndrome (CIS) and healthy controls.Methods We investigated serum NfL levels in 100 patients with CIS with a short conversion interval to clinically definite multiple sclerosis (MS) (fast converters (FC), median (IQR) conversion time: 110 days (79–139)); 98 patients with non-converting CIS (non-converters (NC), follow-up: 6.5 years (5.3–7.9)); and 92 healthy controls.Results NfL levels were higher in FC (24.1 pg/mL (13.5–51.8)) and NC (19.3 pg/mL (13.6–35.2)) than in healthy controls (7.9 pg/mL (5.6–17.2)) (OR=5.85; 95% CI 2.63 to 13.02; p=1.5×10−5 and OR=7.03; 95% CI 2.85 to 17.34; p=2.3×10−5, respectively). When grouping FC and NC, increased serum NfL concentration was also associated with increasing numbers of T2 hyperintense MRI lesions (OR=2.36; 95% CI 1.21 to 4.59; p=0.011), gadolinium-enhancing lesions (OR=2.69; 95% CI 1.13 to 6.41; p=0.026) and higher disability scores (OR=2.54; 95% CI 1.21 to 5.31; p=0.013) at CIS diagnosis.Conclusions If replicated in future studies, serum NfL may represent a reliable and easily accessible biomarker of early axonal damage in CIS and MS.

U2 - 10.1136/jnnp-2014-309690

DO - 10.1136/jnnp-2014-309690

M3 - Article

C2 - 25716934

SN - 0022-3050

VL - 87

SP - 126

EP - 129

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

IS - 2

ER -